Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

P-RAD: A Randomized Study of Preoperative Chemotherapy, Pembrolizumab and No, Low or High Dose RADiation in Node-Positive, HER2-Negative Breast Cancer

NCT04443348 is registered in ClinicalTrials.gov with Laura M. Spring, MD as lead sponsor.

NCT NCT04443348
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04443348 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
P-RAD: A Randomized Study of Preoperative Chemotherapy, Pembrolizumab and No, Low or High Dose RADiation in Node-Positive, HER2-Negative Breast Cancer
Lead sponsor
Laura M. Spring, MD
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 16, 2020
Completion date
December 31, 2026
Enrollment
120 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

biopsy-proven, positive lymph node(s), hormone receptor positive (hr+), her2-negative breast cancer, triple negative breast cancer